Dapagliflozin

Limits on what this shows

• Key negative or null findings: No dapagliflozin-specific study reporting worsened mitochondrial function, reduced mitochondrial DNA copy number, or impaired oxidative phosphorylation capacity was found in this search.
• At-risk subgroups: None identified for harm. All four studies used disease or toxic-stress models (diabetes, cardiorenal syndrome, methamphetamine exposure), so the protective signal is disease-context-dependent and has not been tested in metabolically healthy tissue.

Regulatory status

The FARXIGA label carries no mitochondrial toxicity warning; its cautions relate to euglycemic diabetic ketoacidosis risk (a metabolic, ketogenic-shift effect, not a labeled mitochondrial-injury finding).

Population evidence

No dapagliflozin-specific human study measuring mitochondrial function directly was located. Four dapagliflozin-specific Tier B animal/cell studies were found, all reporting protection: dapagliflozin activated the AMPK/PGC-1α/SIRT3 pathway to improve mitochondrial function in a high-glucose atrial fibrillation model (Li X et al, 2026); restored DUSP1-dependent mitochondrial quality control in a cardiorenal syndrome mouse model (Li Z et al, 2026); reduced myocardial mitochondrial damage under diabetic conditions by targeting sortilin (Gao Y et al, 2025); and alleviated mitochondrial damage in a methamphetamine-induced cardiomyopathy mouse model (He S et al, 2022).

Mechanism

Proposed mechanisms vary by model (AMPK/PGC-1α/SIRT3 activation, DUSP1 signaling, sortilin trafficking) but converge on dapagliflozin supporting mitochondrial quality-control pathways under metabolic or toxic stress, rather than degrading them. No mechanism for drug-induced mitochondrial harm was identified in the literature searched.

Counter-evidence held on record

All four sources are animal or in vitro models (Tier B), none is dapagliflozin-specific in humans, and each uses a different induced-stress paradigm, so the consistency should be read as directionally reassuring rather than as a settled human finding. Framing caution: this is a reverse-direction, protective mechanistic signal, not a deficiency or burden claim. The consumer-facing surface must not present dapagliflozin as damaging mitochondria; if anything, the mechanistic literature argues the opposite, and this entry exists to document that absence of a burden signal explicitly rather than silently.

Limits on what this shows

• Key negative or null findings: No dapagliflozin-specific source reporting a drug-induced increase in oxidative stress markers was found. A class-level narrative review (Pawlos A et al, 2021, Molecules) on SGLT2 inhibitors' neuroprotective, antioxidant-associated effects supports the same direction at the class level but is not dapagliflozin-stratified for every claim within it.
• At-risk subgroups: None identified for harm; all disease-model studies were conducted in hyperglycemic, diabetic-kidney-disease, or toxic-stress contexts, so generalization to non-diabetic or healthy tissue is not established.

Regulatory status

No oxidative-stress-specific adverse reaction or monitoring requirement appears in the FARXIGA label.

Population evidence

No dapagliflozin-specific human RCT directly measuring systemic oxidative stress markers (e.g., malondialdehyde, F2-isoprostanes, 8-OHdG) with verified full-text results was located. Tier B dapagliflozin-specific evidence: SIRT1 activation preventing oxidative-stress-induced endothelial dysfunction (Zhou Y et al, 2023); protection of human proximal tubular cells against oxidative-stress-induced injury in vitro (Zaibi N et al, 2021, PLoS One); suppression of NOX- and SGLT2-dependent oxidative stress in lens cells (Chen YY et al, 2019); reduced oxidative stress and AIM2-dependent pyroptosis via SIRT1 in a diabetic kidney disease model (Wang H et al, 2026); and reduced oxidative stress and ferroptosis via the CYP450s/ROS pathway in diabetic nephropathy (Liang H et al, 2025), all animal or in vitro. A further title (Shi Y et al, 2025, Diabetol Metab Syndr) reports dapagliflozin's effects on podocyte damage and oxidative stress in patients with diabetic nephropathy, which by its title may be a human study, but its full text could not be independently opened in this research session, so no statistic from it is cited.

Mechanism

Proposed mechanisms across these studies (SIRT1 activation, NOX suppression, CYP450/ROS pathway modulation) converge on dapagliflozin reducing, rather than generating, reactive oxygen species under hyperglycemic or toxic stress, plausibly linked to reduced glucotoxicity from the drug's own glucosuric mechanism rather than a separate antioxidant action.

Counter-evidence held on record

Every dapagliflozin-specific source located is Tier B (cell or animal) or unverifiable full text; no Tier A human oxidative-stress biomarker trial was found in either direction. The one possibly-human title (Shi Y et al, 2025) is held on record as unverified rather than cited for any number. Framing caution: this is a reverse-direction, antioxidant-leaning mechanistic signal, not a deficiency or oxidative-burden claim. It must not be marketed as a proven antioxidant benefit for consumers; it is recorded here to show the search was conducted and what it found, which was the opposite of a burden signal.

Limits on what this shows

• Key negative or null findings: In DAPA-HF, dapagliflozin's benefit on the primary outcome was preserved regardless of baseline iron status (hazard ratio 0.74 in iron-deficient patients, 0.81 in iron-replete patients), meaning the iron-marker shift did not translate into worse outcomes for iron-deficient patients on the drug. The RCT found no significant change in ferroportin (the cellular iron-export transporter) expression, indicating the effect is not a uniform iron-handling disruption. Neither source reported a treatment-arm increase in diagnosed iron-deficiency anemia incidence.
• At-risk subgroups: Patients with heart failure with reduced ejection fraction already being evaluated for intravenous iron therapy (a distinct, evidence-based intervention studied in trials such as AFFIRM-AHF and IRONMAN, outside this drug) are the group where a ferritin/transferrin-saturation shift attributable to dapagliflozin itself is most relevant to interpret correctly rather than mistake for worsening iron deficiency.

Regulatory status

Not listed as an iron-specific adverse reaction or monitoring requirement in the FARXIGA label; the label's hematologic signal (addressed under Oxygen delivery/utilization below) is a hemoglobin/hematocrit rise, not an iron-deficiency warning.

Population evidence

Two independent dapagliflozin-specific Tier A sources. (1) Randomized, double-blind, placebo-controlled trial, n=52 obese adults with type 2 diabetes, dapagliflozin 10 mg/day vs placebo, 12 weeks: dapagliflozin significantly reduced circulating hepcidin and ferritin, significantly increased erythroferrone (a hepcidin inhibitor), produced a transient rise in erythropoietin, significantly raised hemoglobin and hematocrit, and increased plasma transferrin along with transferrin receptor 1/2 expression on mononuclear cells; placebo showed no significant change on any of these. (2) DAPA-HF iron substudy, n=3,009 with baseline iron measurements (heart failure with reduced ejection fraction): transferrin saturation, ferritin, and hepcidin were reduced and total iron-binding capacity and soluble transferrin receptor were increased with dapagliflozin compared with placebo, described by the authors as dapagliflozin "appearing to increase iron use."

Mechanism

Proposed as a downstream consequence of the drug's glucosuria-driven improvement in renal cortical oxygenation (reduced proximal-tubular reabsorptive workload lowers local oxygen consumption), which increases erythropoietin output and, in the RCT above, was associated with decreased HIF-1α expression and increased its inhibitor prolyl-hydroxylase-2, plus a proposed anti-inflammatory effect on hepcidin. This is mechanistically distinct from the drug's own glucosuric/osmotic-diuretic mechanism already described in the pharmacokinetic panel; it is a secondary consequence of that mechanism's downstream hematologic effect, not the glucosuria itself, and is graded here rather than dismissed under Hard Rule 1.

Counter-evidence held on record

Outcomes in DAPA-HF were directionally favorable in both iron-deficient and iron-replete patients, and the RCT's ferroportin finding was null, arguing against a generalized iron-wasting mechanism. Both sources are describing markers of iron mobilization and erythropoietic demand, not a measured drop in total body iron or a rise in anemia incidence. Framing caution: this is presented as a mobilization/utilization signal tied to the drug's beneficial erythropoietic effect, not as a dietary iron-deficiency claim, and must never be used to suggest routine iron supplementation. Any decision about iron repletion in a patient on dapagliflozin, especially one with heart failure or CKD already being managed for iron status, belongs with the prescriber; this dossier makes no dosing recommendation.

Limits on what this shows

• Key negative or null findings: Not applicable; there is no study to report a null result from.
• At-risk subgroups: None identified, because none can be identified from an absent evidence base.
• Why no grade: Governance requires both (a) no Tier B/C evidence and (b) no circulating consumer claim to rebut before an axis is left ungraded rather than colored. Both conditions are met here: no study at any tier was found, and no consumer drug-nutrient depletion source encountered in this research session lists dapagliflozin or the SGLT2 inhibitor class against copper. This is not evidence of safety; it is an unaddressed question, and it is printed as such rather than defaulted to white (which would require an actual claim to rebut) or yellow (which would require at least a mechanistic or class-level source).

Regulatory status

No copper-related finding appears in the FARXIGA label.

Population evidence

None located. A PubMed search combining dapagliflozin with copper, trace-element, and mineral-status terms returned zero results on September 10, 2026. No SGLT2-inhibitor-class (Tier C) study measuring copper status was located either.

Mechanism

No mechanism screen category (absorption interference, enzyme induction, renal wasting, cofactor antagonism, dilutional disturbance, microbiome disruption, intake change, or increased utilization) points to copper for this drug. Dapagliflozin is not a chelator, is not a gastric-pH-altering agent, and its minor renal handling effects documented above are specific to glucose, sodium-linked osmotic diuresis, magnesium, and phosphate, none of which share a transporter or handling pathway with copper.

Counter-evidence held on record

Either a dapagliflozin-specific or class-level (canagliflozin, empagliflozin) study directly measuring serum or tissue copper, ceruloplasmin, or a copper-dependent enzyme activity marker, or documentation of an actual circulating consumer claim about dapagliflozin and copper that could then be checked against whatever evidence exists. Framing caution: absence of evidence is not evidence of absence. This entry must never be read by the consumer-facing surface as reassurance that dapagliflozin is confirmed safe for copper status; it means the question has not been studied.

Limits on what this shows

• Key negative or null findings: Both dapagliflozin-specific animal studies describe the microbiota shift as accompanying improvement (beta-cell regeneration, reduced nephropathy), not harm or dysbiosis-associated injury, which argues against framing this as a "risk" in the sense of harm, only as a documented compositional change.
• At-risk subgroups: None identified for harm. Confounding by indication is substantial here: type 2 diabetes, obesity, and diabetic kidney disease are all independently associated with altered gut microbial composition before any drug is started, and none of the studies located separate the drug's contribution from the underlying disease's own microbiome effect using a pre/post-treatment or disease-matched design.

Regulatory status

No gut microbiome or dysbiosis-related warning appears in the FARXIGA label.

Population evidence

Two dapagliflozin-specific Tier B animal studies: dapagliflozin reshaped gut microbiota and modulated tryptophan-metabolism-related metabolites, linked to beta-cell regeneration, in db/db mice (Jiang Y et al, 2024, Diabetes); and a gut-kidney interaction reinforced dapagliflozin's benefit in a diabetic nephropathy mouse model (Ni Y et al, 2025, Am J Physiol Cell Physiol). Class-level (Tier C, different SGLT2 inhibitor in the cohort) evidence: empagliflozin altered gut microbiota alongside improvement in diabetic nephropathy in mice (Deng L et al, 2022); empagliflozin's gut microbiota composition predicted treatment response in a human study of MASLD patients without diabetes (Ng HY et al, 2025, Liver International); and luseogliflozin changed gut microbiota and metabolites differently from a low-carbohydrate diet in db/db mice (Hata S et al, 2022, Nutrients).

Mechanism

Proposed mechanism in the dapagliflozin-specific mouse studies is indirect: reduced hyperglycemia and improved renal/metabolic status change the gut environment and microbial metabolite output (notably tryptophan-pathway metabolites linked to GLP-1 signaling), rather than a direct drug-gut interaction, since dapagliflozin is not a gut-active or antibiotic-like compound and undergoes minimal fecal excretion of unchanged parent drug per the pharmacokinetic panel above.

Counter-evidence held on record

No dapagliflozin-specific human microbiome study was found in either direction. The class-level human study located (Ng HY et al, 2025) used empagliflozin, not dapagliflozin, and cannot be transferred to dapagliflozin above yellow per this dossier's tier rules. Framing caution: confounding by indication is presumed until actively excluded, per this dossier's hard rules, and none of the sources located excludes it. This entry must not be presented as evidence that dapagliflozin harms gut health; the animal data available associate the microbiota shift with metabolic improvement, not injury.

Limits on what this shows

• Key negative or null findings: No dapagliflozin-specific source located reported a decrease in hemoglobin, hematocrit, or oxygen-carrying capacity. A separate dapagliflozin-specific title on short-term peak VO2 changes across iron status in heart failure (Lorenzo M et al, 2023, JACC Heart Fail) was identified as directly relevant to this entry, but its full text could not be opened in this research session (repeated access block), so it is listed in sources with that limitation and not cited for any figure.
• At-risk subgroups: None identified for harm from the increase itself; the corollary caution is the same as in the Iron entry, that clinicians managing anemia or polycythemia should be aware hemoglobin/hematocrit may trend upward on this drug for reasons unrelated to iron repletion or erythropoiesis-stimulating therapy.

Regulatory status

Not listed as a specific adverse reaction requiring monitoring in the FARXIGA label, though hematologic parameter shifts are a recognized feature of the drug's clinical effect profile in its outcome trials.

Population evidence

The same 12-week RCT cited in the Iron entry above (Ghanim H et al, 2020, n=52) found dapagliflozin significantly increased hemoglobin concentration and hematocrit versus placebo, alongside a transient erythropoietin rise. A pooled analysis of 14 dapagliflozin clinical trials (n=5,325 people with type 2 diabetes) was identified addressing hemoglobin/anemia-related endpoints (Stefansson BV et al, 2021, Data Brief); its listing-level summary confirms the trial-count and sample size, but its full-text effect sizes could not be independently verified in this research session, so no numeric result from it is cited beyond what is stated here.

Mechanism

Proposed as a consequence of improved renal cortical oxygenation following reduced proximal-tubular reabsorptive workload (the same mechanism proposed for the Iron entry's erythropoietin rise), secondarily increasing erythropoietin-driven red cell mass and hemoglobin. This is a downstream hematologic consequence of the drug's own glucosuric mechanism, not the glucosuria itself, consistent with Hard Rule 1.

Counter-evidence held on record

The RCT finding is Tier A but from a single 52-patient, 12-week, single-center trial; broader confirmation from the pooled 14-trial dataset could not be independently verified for its specific effect size in this session and is flagged accordingly rather than cited on faith. Framing caution: this is an excess/enhancement signal, not a deficiency, and shares its underlying mechanism and evidence base with the Iron entry above; the two are cross-referenced in the overlap map below to avoid double-counting the same hemoglobin/hematocrit finding as two separate discoveries. Nothing here should be read as license to skip anemia workup in a patient on dapagliflozin who nonetheless presents with low hemoglobin.

Limits on what this shows

• Key negative or null findings: No dapagliflozin-specific source reporting impaired ATP production, reduced myocardial energy reserve, or a negative phosphocreatine/ATP ratio change was found. No human confirmatory data exist either direction for dapagliflozin specifically; the entire evidentiary basis is two animal studies.
• At-risk subgroups: None identified for harm. Both supporting studies used disease-stress models (pulmonary arterial hypertension right heart failure, diabetic kidney disease), so extrapolation to a healthy myocardium is not established.

Regulatory status

No ATP-production or cardiac-energetics-specific finding appears in the FARXIGA label.

Population evidence

A dapagliflozin-specific search for human cardiac energetics data (31-phosphorus magnetic resonance spectroscopy, phosphocreatine/ATP ratio) returned zero results in this research session; no such study, dapagliflozin-specific or class-level, was located. Tier B dapagliflozin-specific animal evidence: dapagliflozin ameliorated pulmonary-arterial-hypertension-induced right heart failure via enhanced ketone body metabolism and mitochondrial function (Xu W et al, 2026, Eur J Pharmacol); and dapagliflozin improved diabetic kidney disease partly by inhibiting ferroptosis through beta-hydroxybutyrate (a ketone body) production (Tian Y et al, 2025, Renal Failure).

Mechanism

Proposed mechanism is the "thrifty substrate" hypothesis common in the SGLT2-inhibitor cardiology literature: glucosuria-driven mild ketosis increases circulating beta-hydroxybutyrate availability as an alternative, more oxygen-efficient myocardial fuel. This is downstream of the drug's own glucosuric mechanism and is graded, not dismissed, per the same Hard Rule 1 logic applied to the Iron and Oxygen delivery entries; it is not itself the glucosuria.

Counter-evidence held on record

Both supporting sources are Tier B animal studies; no dapagliflozin-specific or class-level human cardiac energetics study was located despite a dedicated search, so this remains theoretical for humans regardless of the animal-data direction. Framing caution: this is a proposed enhancement mechanism, not a deficit, and must not be presented to consumers as a proven human cardiac-energy benefit. It overlaps mechanistically with the Mitochondrial Burden entry above; the overlap map below states which entry counts the shared ketone-body source material.